BioArctic Neuroscience AB |
 |
Concept Development |
Lead Discovery |
Lead Optimization |
Preclinical Development |
Phase I |
Phase II |
Phase III |
Launch |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Project: |
|
||||||||||||||||
BioArctic Neuroscience AB
BioArctic Neuroscience develops new treatments for Alzheimer’s disease and other neurodegenerative diseases. In 2005 the company initiated a research collaboration with Eisai in Japan, a global leader in the treatment of Alzheimer’s disease. The company recently initiated a clinical Phase I/II study on 80 Alzheimer’s patients.
| Contact: Pär Gellerfors, CEO | +46 73 382 88 56| par.gellerfors@bioarctic.se | www.bioarctic.se |